Mechanism and current status of simvastatin in treatment of cirrhotic portal hypertension / 临床肝胆病杂志

ABSTRACT

Besides related etiologies, portal hypertension (PHT) is considered an important physiological link in promoting liver dysfunction. Literature review has shown that compared with the conventional drugs for the prevention and treatment of PHT, simvastatin can induce the expression of Kruppel-like factor-2 and nitric oxide to improve liver function and reduce cirrhotic portal venous pressure. Related analysis shows that simvastatin can be widely used in clinical practice to improve portal vein hemodynamics in cirrhotic patients.